Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Chronic Lymphocytic Leukemia
Related studies linked through entity extraction aliases.
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE4
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE1
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE2
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- N/A
Mosunetuzumab for CLL MRD Clearance
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE1
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE2
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
Evaluation of Skin Tests in Biotherapy Allergies
- Status
- RECRUITING
- Phase
- NA
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Status
- RECRUITING
- Phase
- PHASE3
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Status
- RECRUITING
- Phase
- PHASE4
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
- Status
- RECRUITING
- Phase
- PHASE2
Time Restricted Eating in Haematological Malignancies
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2